Heart Valve Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HRT012 MIFTS: 52	Heart Valve Disease Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Heart Valve Disease

MalaCards integrated aliases for Heart Valve Disease:

Name: Heart Valve Disease ¹¹ ¹⁴ ⁶³ ¹⁶ ⁷¹

Valvular Heart Disease ¹¹ ¹⁴ ⁷⁵

Heart Valve Diseases ⁴¹ ⁴³ ³³

Valvular Heart Diseases ⁵³

Heart Valve Prolapse ⁴³

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the circulatory system

Heart valve diseases

Heart valve diseases, unspecified

External Ids:

Disease Ontology ¹¹ DOID:4079

MeSH ⁴³ D006349 D016127

NCIt ⁴⁹ C45525

SNOMED-CT ⁶⁸ 368009 398995000

EFO ¹⁶ EFO_0009551

ICD11 ³³ 1121431779 1121431779/unspecified

UMLS ⁷¹ C0018824 C0079485

Sources

Summaries for Heart Valve Disease

MedlinePlus: ⁴¹ What are heart valve diseases? Heart valve disease happens when one or more of your heart valves don't work well. Your heart has four valves: the tricuspid, pulmonary, mitral, and aortic valves. The valves have flaps that open and close. The flaps make sure that blood flows in the right direction through your heart and to the rest of your body. When your heart beats, the flaps open to let blood through. Between heartbeats they close to stop the blood from flowing backwards. If one or more of your heart valves doesn't open or close correctly, it can affect your blood flow and strain your heart. Fortunately, treatment helps most valve diseases. What are the types of heart valve diseases? Heart valves can have three basic kinds of problems: Regurgitation, or backflow, happens when the flaps of a valve don't close tightly. This allows the blood to leak backwards. A common cause of regurgitation is prolapse, where the flaps of the valve flop or bulge back. Prolapse most often affects the mitral valve. Stenosis happens when the flaps of a valve become thick, stiff, or stuck together. This prevents the heart valve from opening all the way. Not enough blood can pass through the valve. Aortic valve stenosis is a common type of stenosis. It affects the valve that controls blood flow into the large artery that carries blood out of the heart to the body. Atresia happens when a heart valve did not form properly and does not have an opening for blood to pass through. Sometimes a valve can have both regurgitation and stenosis. What causes heart valve diseases? Some people are born with heart valve disease. This is called congenital heart valve disease. It can happen alone or along with other congenital heart defects. Heart valve disease can also develop over time as you get older or have certain conditions that affect the heart. Who is more likely to develop heart valve diseases? Your chance of having heart valve disease is higher if: You are older. With age, the heart valves can become thick and stiff. You have or have had other conditions that affect your heart and blood vessels. These include: Rheumatic fever. An untreated strep throat can become rheumatic fever, which can harm the heart valves. The damage may not show up for years. Today, most people take antibiotics to cure strep throat before it can cause heart valve damage. Endocarditis. This is a rare infection in the lining of the heart and heart valves. It is usually caused by bacteria in the bloodstream. A heart attack. Heart failure. Coronary artery disease, especially when it affects the aorta (the large artery that carries blood from the heart to the body). High blood pressure. High blood cholesterol. Diabetes. Obesity and overweight. Lack of physical activity. A family history of early heart disease: A father or brother who had heart disease younger than 55. A mother or sister who had heart disease younger than 65. You were born with an aortic valve that wasn't formed right. Sometimes this will cause problems right away. Other times, the valve may work well enough for years before causing problems. What are the symptoms of heart valve diseases? Many people live their whole lives with a heart valve that doesn't work perfectly and never have any problems. But heart valve disease may get worse slowly over time. You may develop signs and symptoms, such as: Shortness of breath (feeling like you can't get enough air) Fatigue Swelling in your feet, ankles, abdomen (belly), or the veins in your neck Chest pain when you're physically active Arrhythmia, a problem with the rate or rhythm of your heartbeat Dizziness or fainting If you don't get treatment for heart valve disease, the symptoms and strain on your heart may keep getting worse. What other problems can heart valve diseases cause? When the valves don't work well, your heart has to pump harder to get enough blood out to the body. Without treatment, this extra workload on your heart can lead to: Heart failure Stroke Blood clots Sudden cardiac arrest or death How is heart valve disease diagnosed? Your health care provider may listen to your heart with a stethoscope and hear that your heart makes abnormal sounds, such as a click or a heart murmur. These sounds may mean a valve isn't working normally. The provider will usually refer you to a cardiologist, a doctor who specializes in heart diseases. The doctor will also listen to your heart and will do a physical exam. You will also likely need to have one or more heart tests. What are the treatments for heart valve diseases? Most heart valve problems can be treated successfully. Treatment may include: Medicines to control your symptoms and keep your heart pumping well Heart-healthy lifestyle changes to treat other related heart conditions Surgery to repair or replace a valve It's possible that you may need surgery, even if you don't have symptoms. Fixing the valve can help can prevent future heart problems. There are many ways to do heart valve surgery. You and your doctor can decide what's best for you, based on your valve problem and general health. Heart valve repair surgery has fewer risks than heart valve replacement. So, when repair is possible, it's preferred over valve replacement. In some cases, valve replacement is necessary. There are 2 types of replacement valves: Biologic valves made from pig, cow, or human tissue. These valves tend to wear out after 10 to 15 years, but some may last longer. Mechanical (human-made) valves usually don't wear out. But with a mechanical valve, you usually have to take blood thinners for the rest of your life to prevent blood clots. And your risk of endocarditis (a heart infection) is higher than with a biologic valve. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Heart Valve Disease, also known as valvular heart disease, is related to rheumatic heart disease and tricuspid valve stenosis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Heart Valve Disease is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are MicroRNAs in cardiomyocyte hypertrophy and miRNAs involvement in the immune response in sepsis. The drugs Acetylcysteine and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include Heart, and related phenotype is homeostasis/metabolism.

PubMed Health : ⁶³ Heart valve disease: Heart valve disease occurs if one or more of your heart valves don't work well. The heart has four valves: the tricuspid (tri-CUSS-pid), pulmonary (PULL-mun-ary), mitral (MI-trul), and aortic (ay-OR-tik) valves. These valves have tissue flaps that open and close with each heartbeat. The flaps make sure blood flows in the right direction through your heart's four chambers and to the rest of your body.

Disease Ontology: ¹¹ A heart disease involving one or more of the four valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right).

Wikipedia: ⁷⁵ Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of... more...

Sources

Related Diseases for Heart Valve Disease

Diseases related to Heart Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 608)

#	Related Disease	Score	Top Affiliating Genes
1	rheumatic heart disease	32.4	NPPB ELN ACE
2	tricuspid valve stenosis	32.3	SERPINA3 NPPB
3	tricuspid valve disease	32.2	REN NR3C2 NPPB FBN1 CRP ACE
4	dilated cardiomyopathy	31.5	SERPINA3 REN NR3C2 NPPB NPPA MIR499A
5	pericarditis	31.2	NPPB CRP ACE
6	aortic valve insufficiency	31.1	REN NPPB FBN1 ELN CRP ACE
7	mitral valve stenosis	31.1	SERPINA3 REN NR3C2 NPPB NPPA CRP
8	infective endocarditis	31.1	NPPB CRP CNMD ACE
9	mitral valve insufficiency	31.0	REN NR3C2 NPPB NPPA MIR423 FBN1
10	arteries, anomalies of	31.0	SERPINA3 REN MIR499A MIR423 MIR29B1 MIR21
11	tricuspid valve insufficiency	30.9	REN NR3C2 NPPB FBN1 CRP ACE
12	kawasaki disease	30.9	NPPB ELN CRP
13	aortic valve disease 2	30.9	SERPINA3 REN NPPB NPPA MIR423 MIR29B1
14	constrictive pericarditis	30.9	REN NPPB CRP ACE
15	lipoprotein quantitative trait locus	30.9	SERPINA3 REN NPPB NPPA MIR499A MIR423
16	pericardial effusion	30.9	REN NPPB NPPA CRP ACE
17	kidney disease	30.9	REN NR3C2 NPPB NPPA MIR21 MIR199A1
18	systemic scleroderma	30.8	MIR21 FBN1 CRP ACE
19	stroke, ischemic	30.8	SERPINA3 REN NR3C2 NPPB NPPA MIR21
20	peripheral vascular disease	30.8	SERPINA3 REN MIR126 CRP ACE
21	migraine with or without aura 1	30.8	SERPINA3 REN CRP APOH ACE
22	nonbacterial thrombotic endocarditis	30.8	CRP APOH
23	aortic valve disease 1	30.8	REN NPPB MIR423 MIR29B1 MIR21 MIR204
24	central sleep apnea	30.8	REN NPPB CRP ACE
25	sleep apnea	30.8	REN NPPB CRP ACE
26	cardiac tamponade	30.8	REN NPPB CRP ACE
27	third-degree atrioventricular block	30.8	REN NPPB CRP ACE
28	ventricular septal defect	30.7	NPPB NPPA MIR499A MIR423 MIR199A1
29	hypersensitivity vasculitis	30.7	SERPINA3 REN CRP ACE
30	mitral valve disease	30.7	SERPINA3 REN NR3C2 NPPB NPPA MIR423
31	aortic aneurysm	30.7	REN MIR29B1 MIR21 MIR126 FBN1 ELN
32	apnea, obstructive sleep	30.7	REN NR3C2 NPPB CRP ACE
33	deficiency anemia	30.7	SERPINA3 REN MIR126 CRP ACE
34	libman-sacks endocarditis	30.7	CRP APOH
35	lipid metabolism disorder	30.7	SERPINA3 REN MIR21 MIR199A1 MIR126 CRP
36	orthostatic intolerance	30.6	REN MIR423 FBN1 ELN CRP ACE
37	mediastinum teratoma	30.6	CRP ACE
38	cardiogenic shock	30.6	NPPB NPPA
39	pulmonary valve insufficiency	30.6	REN NPPB FBN1 CRP ACE
40	atrioventricular block	30.6	NPPB CRP ACE
41	eclampsia	30.6	REN APOH ACE
42	hypertrophic cardiomyopathy	30.6	SERPINA3 REN NR3C2 NPPB NPPA MIR499A
43	alcoholic cardiomyopathy	30.6	REN NPPB ACE
44	right bundle branch block	30.6	NPPB CRP ACE
45	inferior myocardial infarction	30.6	NPPB ACE
46	decubitus ulcer	30.6	MIR21 ELN CRP
47	pulmonary hypertension	30.6	REN NPPB NPPA MIR21 MIR204 ELN
48	syphilis	30.6	CRP APOH ACE
49	henoch-schoenlein purpura	30.6	SERPINA3 CRP ACE
50	sleep disorder	30.5	REN CRP ACE

Graphical network of the top 20 diseases related to Heart Valve Disease:

Sources

Symptoms & Phenotypes for Heart Valve Disease

UMLS symptoms related to Heart Valve Disease:

angina pectoris; chest pain; edema; undiagnosed heart murmur

MGI Mouse Phenotypes related to Heart Valve Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	9.47	ACE APOH CNMD CRP CTF1 ELN

Sources

Drugs & Therapeutics for Heart Valve Disease

PubMed Health treatment related to Heart Valve Disease: ⁶³

Currently, no medicines can cure heart valve disease . However, lifestyle changes and medicines often can successfully treat symptoms and delay problems for many years. Eventually, though, you may need surgery to repair or replace a faulty heart valve. The goals of treating heart valve disease might include: Preventing, treating, or relieving the symptoms of other related heart conditions. Protecting heart valves from further damage. Repairing or replacing faulty valves when they cause severe symptoms or become life threatening. Replacement valves can be man-made or biological.

Drugs for Heart Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetylcysteine

Approved, Investigational

Phase 4

616-91-1

581 12035

Metoprolol

Approved, Investigational

Phase 4

37350-58-6, 51384-51-1

4171

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Remifentanil

Approved

Phase 4

132875-61-7

60815

Etomidate

Approved

Phase 4

33125-97-2

667484

Thiopental

Approved, Vet_approved

Phase 4

76-75-5

3000715

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Dabigatran

Approved, Investigational

Phase 4

211914-51-1

216210

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Ropivacaine

Approved

Phase 4

84057-95-4

71273 175805

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Isoflurane

Approved, Vet_approved

Phase 4

26675-46-7

3763

Atracurium

Approved, Experimental, Investigational

Phase 4

64228-79-1

47319

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Vecuronium

Approved, Investigational

Phase 4

50700-72-6, 86029-43-8

39765 39764

Carbetocin

Approved, Investigational

Phase 4

37025-55-1

16681432

Oxytocin

Approved, Vet_approved

Phase 4

50-56-6

439302 53477758

Cysteine

Approved, Nutraceutical

Phase 4

52-90-4

594 5862

Thiamine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

70-16-6

1130

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Simendan

Investigational

Phase 4

131741-08-7

Antioxidants

Phase 4

Protective Agents

Phase 4

Chrysarobin

Phase 4

Antiviral Agents

Phase 4

Anti-Infective Agents

Phase 4

Expectorants

Phase 4

Antidotes

Phase 4

N-monoacetylcystine

Phase 4

Respiratory System Agents

Phase 4

Adrenergic beta-Antagonists

Phase 4

Adrenergic beta-1 Receptor Antagonists

Phase 4

Adrenergic Antagonists

Phase 4

Sympatholytics

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Vitamin B1

Phase 4

Phosphodiesterase 3 Inhibitors

Phase 4

Thiamin

Phase 4

Dsuvia

Phase 4

Interventional clinical trials:

(show top 50) (show all 365)

#	Name	Status	NCT ID	Phase	Drugs
1	Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study	Unknown status	NCT02650388	Phase 4
2	The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.	Unknown status	NCT02710747	Phase 4
3	Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients	Unknown status	NCT01610141	Phase 4
4	Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement	Unknown status	NCT03440268	Phase 4	N Acetyl Cysteine;Placebos
5	Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial	Completed	NCT02867930	Phase 4	Dexmedetomidine;Ketofol(ketamine+propofol)
6	The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting	Completed	NCT01210976	Phase 4	levosimendan;placebo
7	Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial	Completed	NCT01384643	Phase 4	Propofol
8	Sildenafil for Improving Outcomes After Valvular Correction	Completed	NCT00862043	Phase 4	Sildenafil Citrate;Placebo
9	Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass	Completed	NCT02136979	Phase 4	Propofol;Sevoflurane
10	Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery	Completed	NCT03280745	Phase 4	Hypertonic saline;0.9% saline
11	The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone.	Completed	NCT01495949	Phase 4	etomidate;thiopentone
12	The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia	Completed	NCT01826149	Phase 4	Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
13	Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery	Completed	NCT01174719	Phase 4	volume replacement;Humanalbumin 5%
14	Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial.	Completed	NCT01477151	Phase 4	Volatile anesthetic
15	The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS)	Completed	NCT00371891	Phase 4
16	Beta Blockade in Mitral Regurgitation	Completed	NCT00166400	Phase 4	metoprolol succinate
17	Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery	Completed	NCT01427621	Phase 4
18	Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients	Completed	NCT02982850	Phase 4	Dabigatran;Acetylsalicylic acid;Warfarin
19	Ultrasound Guided Repeated Bilateral Transversus Thoracis Muscle Plane Block Via Catheter and Postoperative Pain in Cardiac Surgery	Recruiting	NCT04916418	Phase 4	Placebo;Ropivacaine
20	Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery: Randomized Clinical Trial	Recruiting	NCT05079672	Phase 4	Dexmedetomidine;0,9% Saline
21	Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University: Randomized Prospective Comparative Study	Active, not recruiting	NCT04223219	Phase 4	Fentanyl;Fentanyl, Propofol;Dexmedetomidine, Ketamine, Magnesium sulfate
22	Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients With Stenotic Valvular Heart Disease Undergoing Caesarean Section	Not yet recruiting	NCT05110482	Phase 4	Syntocinon;Carbetocin
23	Sugammadex Titration for Reversal of Rocuronium or Vecuronium in Cardiac Surgery Patients	Not yet recruiting	NCT05246397	Phase 4	Sugammadex administration
24	Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial	Withdrawn	NCT00187304	Phase 4
25	Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications	Unknown status	NCT01000233	Phase 2, Phase 3
26	"Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial	Unknown status	NCT00214656	Phase 3	Recombinant Activated Factor VII
27	Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair	Completed	NCT02084069	Phase 3	Atorvastatin
28	Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring	Completed	NCT01591018	Phase 3
29	Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery	Completed	NCT05223361	Phase 3	Six percent hydroxy ethyl starch 130/0.4;Ringer lactate
30	Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial	Completed	NCT02833948	Phase 3	Acetylsalicylic acid;Clopidogrel;Rivaroxaban
31	Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery	Completed	NCT02237495	Phase 2, Phase 3	dexmedetomidine;placebo
32	Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)	Completed	NCT02679261	Phase 3	Atorvastatin;Placebo
33	An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 3 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)	Recruiting	NCT05143177	Phase 2, Phase 3	Evogliptin;Placebo
34	The Safety and Effectiveness of the SAPIEN 3 and SAPIEN 3 Ultra Valve in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification Who Are Not Candidates for Standard Mitral Valve Surgery.	Recruiting	NCT04408430	Phase 2, Phase 3
35	Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery	Terminated	NCT00250965	Phase 3	intravenous magnesium
36	Clinical Trial Comparing a Conventional Median Sternotomy Versus a Minimally Invasive Technique for Aortic Valvular Replacement in Adults	Terminated	NCT00221663	Phase 2, Phase 3
37	Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis	Terminated	NCT03566303	Phase 2, Phase 3	Rivaroxaban 15 mg;Warfarin
38	Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment	Withdrawn	NCT01654042	Phase 3
39	Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience	Unknown status	NCT00921596	Phase 1, Phase 2
40	Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study	Unknown status	NCT02917525	Phase 2
41	A Prospective, Randomized, Multicenter Clinical Study on the High Vacuum Body Cavity Drainage Systems Following Open Heart Surgery	Completed	NCT00581399	Phase 2
42	Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery	Completed	NCT01348074	Phase 2	Double dose
43	CopenHeartVR - A Randomized Clinical Trial Investigating the Effect of Integrated Rehabilitation Versus Usual Care Without Physical Exercise After Heart Valve Surgery.	Completed	NCT01558765	Phase 2
44	A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER	Completed	NCT02303795	Phase 2	Rivaroxaban;Warfarin
45	Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial	Completed	NCT01681095	Phase 2	Custodiol HTK;Cold Blood Cardioplegia
46	N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.	Completed	NCT01704482	Phase 2	N-acetylcysteine;placebo
47	The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study	Completed	NCT02479581	Phase 2
48	Cytokine Clearance With Cytoabsorbant Device During Cardiac Bypass: a Pilot Study	Completed	NCT02775123	Phase 1, Phase 2
49	Nitric Oxide Supplementation to the Extracorporeal Circulation Line as a Method of Nephroprotection in Cardiac Surgery	Completed	NCT03527381	Phase 1, Phase 2	Nitric Oxide
50	A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin	Completed	NCT00356759	Phase 2	Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times

Search NIH Clinical Center for Heart Valve Disease

Cochrane evidence based reviews: heart valve diseases

Sources

Genetic Tests for Heart Valve Disease

Sources

Anatomical Context for Heart Valve Disease

Organs/tissues related to Heart Valve Disease:

MalaCards : Heart, Lung, Bone, Kidney, Brain, Whole Blood, Endothelial

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Heart Valve Disease:

#	Tissue Anatomical CompartmentCell	Relevance
1	Heart Atrioventricular Valves Atrioventricular Valve Cells	Affected by disease
2	Heart Semilunar Valves Semilunar Valve Cells	Affected by disease

Sources

Publications for Heart Valve Disease

Articles related to Heart Valve Disease:

(show top 50) (show all 7517)

#	Title	Authors	PMID	Year
1	Clinical Features and Survival Analysis of Patients after Mechanical Heart Valve Replacement, with an Emphasis on Prosthetic Valve Thrombosis. ⁶² ⁴¹	Tagliari F...Lamas C	36453764	2022
2	Clinical characteristics and risk factors for rebleeding in uremic patients with obscure gastrointestinal bleeding undergoing deep enteroscopy: A multi-center retrospective study in Taiwan. ⁶² ⁴¹	Hung HJ...Huang TY	36449459	2022
3	Short-Term Results on Leaflet Mobility in Patients Undergoing Rheumatic Mitral Valve Repair With an Efficient 4-Step Commissuroplasty Technique. ⁴¹	Tian B...Xu J	36450146	2022
4	A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. ⁵³ ⁶²	Cakir Z...Gundogdu F	20436747	2010
5	Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? ⁵³ ⁶²	Campbell DJ	18307738	2008
6	Predictive value of heart-type fatty acid-binding protein for left ventricular remodelling and clinical outcome of hypertensive patients with mild-to-moderate aortic valve diseases. ⁵³ ⁶²	Iida M...Kamiya K	17392813	2007
7	[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]. ⁵³ ⁶²	Hakuno D...Fukuda K	17339740	2007
8	Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. ⁵³ ⁶²	Burke MA...Cotts WG	17345160	2007
9	Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. ⁵³ ⁶²	Nakamura M...Hiramori K	16043943	2005
10	[PTEN/PI3K pathways are involved in the signal transduction of myocardial remodeling in patients with congestive heart failure]. ⁵³ ⁶²	Yang YJ...Zhu ZM	16029597	2005
11	Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. ⁵³ ⁶²	Freed DH...Dixon IM	15721858	2005
12	Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. ⁵³ ⁶²	Kostopanagiotou G...Smyrniotis V	14973795	2004
13	Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing. ⁵³ ⁶²	Freed DH...Dixon IM	14674704	2003
14	Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. ⁵³ ⁶²	Leszczynski P...Mackiewicz S	14677016	2003
15	Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. ⁵³ ⁶²	Pitt B...Rajagopalan S	14608520	2003
16	3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. ⁵³ ⁶²	Setola V...Roth BL	12761331	2003
17	Antiphospholipid antibodies and the risk of thromboembolic events in valvular heart disease. ⁵³ ⁶²	Bulckaen HG...Millaire A	12630582	2003
18	Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. ⁵³ ⁶²	Xu J...Liang B	12466135	2002
19	Locally different role of atrial natriuretic peptide (ANP) in the pericardial fluid. ⁵³ ⁶²	Soos P...Horkay F	12270761	2002
20	Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease. ⁵³ ⁶²	Yamada Y...Yokota M	9286500	1997
21	Effect of the maze procedure for atrial fibrillation on atrial and brain natriuretic peptide. ⁵³ ⁶²	Nakamura M...Hiramori K	9104915	1997
22	Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis. ⁵³ ⁶²	McHugh NJ...Ring EF	8467615	1993
23	Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. ⁵³ ⁶²	Mathisen P...Simonsen S	8451600	1993
24	Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. ⁵³ ⁶²	Eber B	1611635	1992
25	Atrial natriuretic peptide: pathophysiological considerations. ⁵³ ⁶²	Sahai A...Ganguly PK	1534550	1992
26	Anticardiolipin antibody and stroke: possible relation of valvular heart disease and embolic events. ⁵³ ⁶²	Barbut D...Lockshin M	1933972	1991
27	Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus. ⁵³ ⁶²	Li EK...Cohen MG	1975008	1990
28	Cardiac Involvement in Fabry Disease and the Role of Multimodality Imaging in Diagnosis and Disease Monitoring. ⁶²	Umer M...Kalra DK	36202174	2023
29	Clinical features, myocardial strain and tissue characteristics of heart failure with preserved ejection fraction in patients with obesity: A prospective cohort study. ⁶²	He J...Lu M	36386034	2023
30	Anterior-Posterior versus anterior-lateral electrodes position for electrical cardioversion of atrial fibrillation: A meta-analysis of randomized controlled trials. ⁶²	Eid M...Elbadawi A	36304256	2022
31	Red cell distribution width as a prognosticator in patients with heart failure. ⁶²	Kim M...Kang SM	36460487	2022
32	Emerging role of pericytes in therapy of cardiovascular diseases. ⁶²	Dabravolski SA...Melnichenko AA	36411618	2022
33	Managing Diastolic Dysfunction Perioperatively. ⁶²	Cios TJ...Roberts SM	36473032	2022
34	Hybrid heart valves with VEGF-loaded zwitterionic hydrogel coating for improved anti-calcification and re-endothelialization. ⁶²	Tong Q...Qian Z	36278142	2022
35	Cellular Landscapes of Nondiseased Human Cardiac Valves From End-Stage Heart Failure-Explanted Heart. ⁶²	Shu S...Song J	36200446	2022
36	Valvular heart diseases in immigrants and Swedish-born individuals: a national cohort study. ⁶²	Wandell P...Sundquist K	35792712	2022
37	Crossing the Boundaries of Treatment of Valvular Heart Disease in Patients With Liver Cirrhosis. ⁶²	Gimenez-Mila M...Regueiro A	36155717	2022
38	Advances in Neurocardiology: Focus on Anticoagulation for Valvular Heart Disease With and Without Atrial Fibrillation. ⁶²	Gurol ME...Sposato LA	36337056	2022
39	The importance of big databases in understanding valvular heart disease. ⁶²	Galloo X...Bax JJ	36464940	2022
40	Maternal mortality due to valvular heart disease: a population-based study in Turkey. ⁶²	Yucel A...Kara F	34988858	2022
41	Evolution of non-fatal burden estimates for cardiovascular disease in Australia: a comparison of national and state-wide methodology of burden of disease. ⁶²	Weber C...Katzenellenbogen JM	36395787	2022
42	Surgery in severe valvular heart diseases: when it is too late, too early or right on time? ⁶²	Saade W...Frati G	36349942	2022
43	The leaflet-annulus index in canine myxomatous mitral valve disease. ⁶²	Isaka M...Ueno H	36029573	2022
44	An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program. ⁶²	Guerrini R...Strzelczyk A	35801621	2022
45	Cardiovascular CT, MRI, and PET/CT in 2021: Review of Key Articles. ⁶²	Tzimas G...Dodd JD	36378032	2022
46	Hedinger Syndrome with Intraoperative Carcinoid Crisis - Understanding the Pathophysiology for a Successful Management. ⁶²	Guerrero-Becerra AF...Giraldo JC	34673518	2022
47	Major adverse cardiac events after elective infrarenal endovascular aortic aneurysm repair. ⁶²	Diender E...Holewijn S	35714892	2022
48	Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations. ⁶²	Izzy M...VanWagner LB	35359027	2022
49	Safety and usefulness of left ventricular endomyocardial biopsy in new- onset acute heart failure requiring mechanical support by an Impella® device. ⁶²	Tschope C...Alogna A	35944774	2022
50	MitraClip: a review of its current status and future perspectives. ⁶²	Kataoka A...OCEAN-SHD Family	36469300	2022

Sources

Genes for Heart Valve Disease

Genes related to Heart Valve Disease (0 elite genes):

(show top 50) (show all 55)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NPPB	Natriuretic Peptide B	Protein Coding	16.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16043943 9286500 18307738 (more) 20436747 9104915 17392813 17345160
2	APOH	Apolipoprotein H	Protein Coding	12.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1933972 11787877 12630582 (more) 14677016 1611635 1975008 8467615
3	CNMD	Chondromodulin	Protein Coding	12.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16515361 17339740
4	NPPA	Natriuretic Peptide A	Protein Coding	12.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14973795 8451600 1534550 (more) 12270761
5	MIR499A	MicroRNA 499a	RNA Gene	11.98	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
6	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	11.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14608520
7	MIR21	MicroRNA 21	RNA Gene	10.14	DISEASES inferred ¹⁴ ¹⁴
8	CTF1	Cardiotrophin 1	Protein Coding	9.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14674704 15721858
9	MIR29B1	MicroRNA 29b-1	RNA Gene	9.42	DISEASES inferred ¹⁴ ¹⁴
10	MIR423	MicroRNA 423	RNA Gene	9.13	DISEASES inferred ¹⁴ ¹⁴
11	MIR126	MicroRNA 126	RNA Gene	8.88	DISEASES inferred ¹⁴ ¹⁴
12	ACE	Angiotensin I Converting Enzyme	Protein Coding	8.75	DISEASES inferred ¹⁴
13	MIR199A1	MicroRNA 199a-1	RNA Gene	8.56	DISEASES inferred ¹⁴ ¹⁴
14	CRP	C-Reactive Protein	Protein Coding	8.36	DISEASES inferred ¹⁴
15	MIR146A	MicroRNA 146a	RNA Gene	8.23	DISEASES inferred ¹⁴ ¹⁴
16	SERPINA3	Serpin Family A Member 3	Protein Coding	8.08	DISEASES inferred ¹⁴ ¹⁴
17	MIR204	MicroRNA 204	RNA Gene	8.03	DISEASES inferred ¹⁴ ¹⁴
18	REN	Renin	Protein Coding	8.02	DISEASES inferred ¹⁴
19	ELN	Elastin	Protein Coding	7.99	DISEASES inferred ¹⁴
20	FBN1	Fibrillin 1	Protein Coding	7.92	DISEASES inferred ¹⁴
21	MIR17	MicroRNA 17	RNA Gene	7.85	DISEASES inferred ¹⁴ ¹⁴
22	MIR195	MicroRNA 195	RNA Gene	7.84	DISEASES inferred ¹⁴ ¹⁴
23	MIR505	MicroRNA 505	RNA Gene	7.82	DISEASES inferred ¹⁴ ¹⁴
24	TNNI3	Troponin I3, Cardiac Type	Protein Coding	7.73	DISEASES inferred ¹⁴
25	MIR26B	MicroRNA 26b	RNA Gene	7.67	DISEASES inferred ¹⁴ ¹⁴
26	MIR486-1	MicroRNA 486-1	RNA Gene	7.62	DISEASES inferred ¹⁴ ¹⁴
27	MIR22	MicroRNA 22	RNA Gene	7.55	DISEASES inferred ¹⁴ ¹⁴
28	MIR34A	MicroRNA 34a	RNA Gene	7.53	DISEASES inferred ¹⁴ ¹⁴
29	ALB	Albumin	Protein Coding	7.48	DISEASES inferred ¹⁴
30	MIR424	MicroRNA 424	RNA Gene	7.44	DISEASES inferred ¹⁴ ¹⁴
31	MYH6	Myosin Heavy Chain 6	Protein Coding	7.39	DISEASES inferred ¹⁴
32	MIR374B	MicroRNA 374b	RNA Gene	7.39	DISEASES inferred ¹⁴ ¹⁴
33	MIR218-1	MicroRNA 218-1	RNA Gene	7.37	DISEASES inferred ¹⁴ ¹⁴
34	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	7.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12466135
35	VWF	Von Willebrand Factor	Protein Coding	7.34	DISEASES inferred ¹⁴
36	F2	Coagulation Factor II, Thrombin	Protein Coding	7.32	DISEASES inferred ¹⁴
37	H2AC18	H2A Clustered Histone 18	Protein Coding	7.3	DISEASES inferred ¹⁴ ¹⁴
38	TNNT2	Troponin T2, Cardiac Type	Protein Coding	7.27	DISEASES inferred ¹⁴
39	MIR675	MicroRNA 675	RNA Gene	7.25	DISEASES inferred ¹⁴ ¹⁴
40	TTR	Transthyretin	Protein Coding	7.17	DISEASES inferred ¹⁴
41	MYH7	Myosin Heavy Chain 7	Protein Coding	7.15	DISEASES inferred ¹⁴
42	F3	Coagulation Factor III, Tissue Factor	Protein Coding	7.14	DISEASES inferred ¹⁴
43	IL6	Interleukin 6	Protein Coding	7.14	DISEASES inferred ¹⁴
44	MIR92B	MicroRNA 92b	RNA Gene	7.07	DISEASES inferred ¹⁴ ¹⁴
45	NKX2-5	NK2 Homeobox 5	Protein Coding	7.06	DISEASES inferred ¹⁴
46	MYOM2	Myomesin 2	Protein Coding	7.06	DISEASES inferred ¹⁴
47	EDN1	Endothelin 1	Protein Coding	7.04	DISEASES inferred ¹⁴
48	RUNX2	RUNX Family Transcription Factor 2	Protein Coding	7.01	DISEASES inferred ¹⁴
49	INS	Insulin	Protein Coding	6.99	DISEASES inferred ¹⁴
50	MIR142	MicroRNA 142	RNA Gene	6.98	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Heart Valve Disease

Sources

Expression for Heart Valve Disease

Search GEO for disease gene expression data for Heart Valve Disease.

Sources

Pathways for Heart Valve Disease

Pathways related to Heart Valve Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MicroRNAs in cardiomyocyte hypertrophy ⁷⁴ Show member pathways Cardiac hypertrophic response ⁷⁴	11.19	NPPB NPPA MIR21 MIR199A1 CTF1
2	miRNAs involvement in the immune response in sepsis ⁷⁴	10.92	MIR21 MIR199A1 MIR126

Sources

GO Terms for Heart Valve Disease

Cellular components related to Heart Valve Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.2	SERPINA3 REN NPPB NPPA FBN1 ELN
2	RISC complex	GO:0016442	9.86	MIR126 MIR146A MIR199A1 MIR204 MIR21 MIR29B1
3	extracellular space	GO:0005615	9.72	SERPINA3 REN NPPB NPPA MIR423 MIR29B1

Biological processes related to Heart Valve Disease according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	miRNA-mediated gene silencing	GO:0035195	10.18	MIR499A MIR423 MIR29B1 MIR21 MIR204 MIR199A1
2	regulation of blood pressure	GO:0008217	10.06	REN NPPB NPPA ACE
3	positive regulation of apoptotic process	GO:0043065	10.05	MIR29B1 MIR21 MIR204 MIR146A ACE
4	negative regulation of gene expression	GO:0010629	10.04	MIR29B1 MIR21 MIR199A1 MIR146A ACE
5	negative regulation of angiogenesis	GO:0016525	9.92	APOH CNMD MIR146A MIR21 NPPB
6	blood vessel diameter maintenance	GO:0097746	9.89	NPPB NPPA ACE
7	negative regulation of inflammatory response	GO:0050728	9.84	MIR204 MIR199A1 MIR146A MIR126
8	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.73	MIR499A MIR21 MIR146A
9	negative regulation of endothelial cell proliferation	GO:0001937	9.73	MIR21 MIR146A CNMD APOH
10	positive regulation of potassium ion export across plasma membrane	GO:1903766	9.69	NPPA MIR21
11	positive regulation of vascular endothelial cell proliferation	GO:1905564	9.65	MIR499A MIR21 MIR126
12	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.61	MIR146A MIR21 MIR499A
13	positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903589	9.58	MIR21 MIR146A MIR126
14	positive regulation of metalloendopeptidase activity	GO:1904685	9.55	MIR29B1 MIR21
15	negative regulation of metallopeptidase activity	GO:1905049	9.52	MIR199A1 MIR29B1
16	negative regulation of NIK/NF-kappaB signaling	GO:1901223	9.46	MIR29B1 MIR21 MIR204 MIR146A
17	negative regulation of matrix metallopeptidase secretion	GO:1904465	9.13	MIR29B1 MIR199A1 MIR146A
18	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.1	MIR499A MIR29B1 MIR21 MIR204 MIR146A MIR126

Molecular functions related to Heart Valve Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.5	MIR499A MIR29B1 MIR21 MIR204 MIR199A1 MIR146A
2	hormone receptor binding	GO:0051427	9.46	NPPB NPPA
3	mRNA base-pairing translational repressor activity	GO:1903231	9.23	MIR499A MIR423 MIR29B1 MIR21 MIR204 MIR199A1